Insights
Recon takes an analytical look behind select developments in healthcare
Keep up with Recon Strategy Insights
Get an email each time we publish a new article
Search
- By Marc Herant
Small but real progress in ALS:
Despite enormous public attention and significant effort, ALS remains a disease for which the development of new therapies has been challenging. Animal models showed po…
- By Tess Niewood and Max Holle
OptumCare’s acquisitions usually make headlines. But what happens when the reporters leave? How is clinical capacity managed? What role do micro-acquisitions, recruiting and retirements play in advan…
- By Max Holle
Summary:
We conducted a comparative analysis of the referral networks of orthopedic surgeons in King County (the area around Seattle, WA) and Miami-Dade County.
Similarities
Bigger systems are better…
- By Marc Herant and Anja Schempf
PDF: An ADC renaissance: a resurgence of antibody drug conjugates for cancer
Summary:
Antibody-drug conjugates (ADCs) have seen a record number of approvals in 2020. This comes after a first era of i…
- By Marc Herant
A cheap, low tech intervention for a common Achilles’ heel
When I am out and about, for instance at the grocery store, I am always surprised at the number of people I see with swollen legs. About half…
- By Marc Herant
Stunting and the microbiome
Stunting (low growth for age) affects > 20% of children across the globe and has major impact on the brain, on health, and on opportunities for success in life. The prec…
- By Miriam Alandydy